PL3877402T3 - Leczenie skojarzone nadciśnienia tętniczego - Google Patents

Leczenie skojarzone nadciśnienia tętniczego

Info

Publication number
PL3877402T3
PL3877402T3 PL19881216.6T PL19881216T PL3877402T3 PL 3877402 T3 PL3877402 T3 PL 3877402T3 PL 19881216 T PL19881216 T PL 19881216T PL 3877402 T3 PL3877402 T3 PL 3877402T3
Authority
PL
Poland
Prior art keywords
hypertension
combination treatment
treatment
combination
Prior art date
Application number
PL19881216.6T
Other languages
English (en)
Inventor
Jr John C. Burnett
Nina DZHOYASHVILI
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of PL3877402T3 publication Critical patent/PL3877402T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19881216.6T 2018-11-09 2019-11-08 Leczenie skojarzone nadciśnienia tętniczego PL3877402T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758009P 2018-11-09 2018-11-09
PCT/US2019/060401 WO2020097421A1 (en) 2018-11-09 2019-11-08 Combination treatment for resistant hypertension

Publications (1)

Publication Number Publication Date
PL3877402T3 true PL3877402T3 (pl) 2025-12-01

Family

ID=70612496

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19881216.6T PL3877402T3 (pl) 2018-11-09 2019-11-08 Leczenie skojarzone nadciśnienia tętniczego

Country Status (13)

Country Link
US (2) US20220118054A1 (pl)
EP (2) EP3877402B1 (pl)
JP (2) JP2022506716A (pl)
KR (1) KR20210090229A (pl)
CN (1) CN113727997A (pl)
AU (2) AU2019375988A1 (pl)
BR (1) BR112021008841A2 (pl)
CA (1) CA3119055A1 (pl)
ES (1) ES3047085T3 (pl)
IL (2) IL315007A (pl)
MX (1) MX2021005453A (pl)
PL (1) PL3877402T3 (pl)
WO (1) WO2020097421A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039392A1 (en) * 2021-09-07 2023-03-16 Mayo Foundation For Medical Education And Research Methods and materials for determining pgc target dosage
WO2023039453A2 (en) * 2021-09-09 2023-03-16 Mayo Foundation For Medical Education And Research Dual-function polypeptides and methods for use thereof
US20240116990A1 (en) * 2022-09-19 2024-04-11 Mayo Foundation For Medical Education And Research Compositions and Methods of Treatment Using CRRL 191
EP4669340A1 (en) * 2023-02-22 2025-12-31 Mayo Foundation for Medical Education and Research Methods of treating hypertension with metabolic syndrome using manp
WO2025054172A1 (en) * 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof
WO2025184377A1 (en) * 2024-02-28 2025-09-04 Mayo Foundation For Medical Education And Research Methods for sustained lowering of blood pressure using manp

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161521A (en) 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
KR930009516B1 (ko) 1990-04-27 1993-10-06 미쓰비시덴키 가부시키가이샤 진동검출기 및 그의 고유진동주파수 조정방법
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6969480B2 (en) 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
ATE424848T1 (de) 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
US20100266704A1 (en) 2008-12-15 2010-10-21 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US10004754B2 (en) * 2014-03-14 2018-06-26 Madeleine Pharmaceuticals Pty Ltd. ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
US11072642B2 (en) * 2016-11-09 2021-07-27 Mayo Foundation For Medical Education And Research MANP analogues

Also Published As

Publication number Publication date
EP3877402A1 (en) 2021-09-15
IL282958B2 (en) 2025-01-01
US20220118054A1 (en) 2022-04-21
KR20210090229A (ko) 2021-07-19
WO2020097421A1 (en) 2020-05-14
MX2021005453A (es) 2021-09-08
ES3047085T3 (en) 2025-12-03
CN113727997A (zh) 2021-11-30
IL282958A (en) 2021-06-30
IL282958B1 (en) 2024-09-01
US20250381249A1 (en) 2025-12-18
AU2025203575A1 (en) 2025-06-05
AU2019375988A1 (en) 2021-05-27
EP4603090A1 (en) 2025-08-20
JP2024156691A (ja) 2024-11-06
CA3119055A1 (en) 2020-05-14
EP3877402B1 (en) 2025-07-16
JP2022506716A (ja) 2022-01-17
BR112021008841A2 (pt) 2021-08-31
EP3877402A4 (en) 2022-07-27
IL315007A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
IL282958A (en) Combined treatment of resistant hypertension
GB201813876D0 (en) Treatment
HUE061444T2 (hu) Készítmények a magas vérnyomás kezelésére
GB201819164D0 (en) Artificial-intelligence-assisted surgery
IL288937A (en) Improved treatment using eyp001
GB201800546D0 (en) Treatment
PL3628252T3 (pl) System krioaplikatora kardiochirurgicznego
ZA202006591B (en) Compositions for the treatment of hypertension
SG11202102878TA (en) Treatment methods
SG11202102827YA (en) Treatment methods
IL290319A (en) Compound for combined treatment
GB201914296D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201909661D0 (en) Early entry
GB201807046D0 (en) Combination
SG11202102683XA (en) Treatment for obesity
GB201902579D0 (en) Treatment
SG10201910408QA (en) Device for treating dysarthrosis
GB2571849B (en) Treatments for cachexia
GB201810111D0 (en) Camshaft
GB201912760D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201911603D0 (en) Treatment
GB201910755D0 (en) Treatment